The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Yassine, Hussein N ^a   Rawat, Varun ^a   Mack, Wendy J ^a   Quinn, Joseph F ^b   Yurko Mauro, Karin ^c   Bailey Hall, Eileen ^c   Aisen, Paul S ^a   Chui, Helena C ^a   Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c DSM NUTRITIONAL PRODUCTS   (United States)

Author keywords

Alzheimer's disease; Amyloid; APOE; Cerebrospinal fluid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; DOCOSAHEXAENOIC ACID; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E4; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; COGNITION; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; FOLLOW UP; GENOTYPE; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUPPLEMENTATION; BLOOD; CLINICAL TRIAL; DIET THERAPY; DIETARY SUPPLEMENT; DOUBLE BLIND PROCEDURE; GENETICS; MULTICENTER STUDY; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84976402651     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0194-x     Document Type: Article

References (45)

1. Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-8.
2. Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-3.
3. Genin E et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903-7.
4. Cunnane SC et al. Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res. 2009;48(5):239-56.
5. Cunnane SC et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2012;29(3):691-7.
6. Söderberg M et al. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 1991;26(6):421-5.
7. Corrigan F et al. Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol. 1998;30(2):197-207.
8. Prasad MR et al. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 1998;23(1):81-8.
9. Freund-Levi Y et al. ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD Study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402-8.
10. Chiu CC et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1538-44.
11. Johnson EJ et al. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci. 2008;11(2):75-83.
12. Quinn JF et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903-11.
13. Yurko-Mauro K et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6):456-64.
14. Vellas B et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. J Prev Alzheimers Dis. 2014;1:13-22.
15. van de Rest O et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008;71(6):430-8.
16. Daiello LA et al. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement. 2015;11(2):226-35.
17. Huang TL et al. Benefits of fatty fish on dementia risk are stronger for those without APOE ϵ4. Neurology. 2005;65(9):1409-14.
18. Whalley LJ et al. n-3 Fatty acid erythrocyte membrane content, APOE ϵ4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87(2):449-54.
19. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15(12):771-85.
20. Vandal M et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem. 2014;129(3):516-26.
21. Calon F. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: key questions and partial answers. Curr Alzheimer Res. 2011;8(5):470-8.
22. Freund-Levi Y et al. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med. 2014;275(4):428-36.
23. Kuratko CN et al. The relationship of docosahexaenoic acid (DHA) with learning and behavior in healthy children: a review. Nutrients. 2013;5(7):2777-810.
24. Arterburn LM et al. Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food. Lipids. 2007;42(11):1011-24.
25. Folch J, Lees M, Sloane-Stanley G. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497-509.
26. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res. 1964;5(4):600-8.
27. Shaw LM et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-13.
28. Esposito G et al. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med. 2008;49(9):1414-21.
29. Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. 2002;68:197-210.
30. Mashek DG, Coleman RA. Cellular fatty acid uptake: the contribution of metabolism. Curr Opin Lipidol. 2006;17(3):274-8.
31. Kuipers RS et al. Fetal intrauterine whole body linoleic, arachidonic and docosahexaenoic acid contents and accretion rates. Prostaglandins Leukot Essent Fatty Acids. 2012;86(1):13-20.
32. Carver JD et al. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull. 2001;56(2):79-85.
33. Purdon A et al. Energy consumption by phospholipid metabolism in mammalian brain. Neurochem Res. 2002;27(12):1641-7.
34. Fonteh AN et al. Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease. PLoS One. 2014;9(6):e100519.
35. Palop JJ et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55(5):697-711.
36. 2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008;11(11):1311-8.
37. 2 by amyloid β-peptides in vitro. Biochemistry. 1996;35(29):9407-14.
38. Rapoport SI. Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):79-85.
39. Cao D et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem. 2009;111(2):510-21.
40. Plourde M et al. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE ϵ4 but not by the common PPAR-α L162V polymorphism in men. Br J Nutr. 2009;102(8):1121-4.
41. Conway V et al. Postprandial enrichment of triacylglycerol-rich lipoproteins with omega-3 fatty acids: lack of an interaction with apolipoprotein E genotype? Lipids Health Dis. 2014;13:148.
42. Samieri C et al. Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. J Lipid Res. 2013;54(9):2559-67.
43. Samieri C et al. ω-3 fatty acids and cognitive decline: modulation by ApoEϵ4 allele and depression. Neurobiol Aging. 2011;32(12):2317. e13-e22.
44. Morris MC et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60(7):940-6.
45. Morris MC et al. Association of seafood consumption, brain mercury level, and APOE ϵ4 status with brain neuropathology in older adults. JAMA. 2016;315(5):489-97.